## Analysis of Chronic Anal Fissure Management ### Key Point: **Botulinum toxin is absolutely contraindicated in myasthenia gravis** because it blocks acetylcholine release at the neuromuscular junction, worsening the underlying pathophysiology. However, it is **NOT contraindicated in immunocompromised patients** — immunosuppression does not affect the local mechanism of action of botulinum toxin in the internal anal sphincter. ### High-Yield: The standard medical management ladder for chronic anal fissure: | Treatment | Mechanism | Healing Rate | Notes | |-----------|-----------|--------------|-------| | Topical nitrates (GTN 0.2%) | ↓ IAS pressure via NO release | 40–60% | Headache common; tolerance develops | | Calcium channel blockers (diltiazem) | ↓ IAS pressure via Ca²⁺ blockade | 50–70% | Fewer systemic side effects than nitrates | | Botulinum toxin (20–25 U) | Blocks acetylcholine at NMJ | 60–80% | Contraindicated in myasthenia gravis | | Lateral internal sphincterotomy | Surgical division of IAS | 90–95% | Small risk of postoperative incontinence (1–5%) | ### Clinical Pearl: **Botulinum toxin contraindications:** - Myasthenia gravis (absolute) - Eaton–Lambert syndrome (absolute) - Neuromuscular junction disorders (absolute) - Immunocompromise is **NOT** a contraindication — the toxin acts locally on the sphincter, not systemically. ### Warning: Do not confuse immunosuppression with neuromuscular disease. Botulinum toxin is safe in HIV, malignancy, and post-transplant patients because the local paralytic effect is independent of immune function. ### Mnemonic: **NITRATE-BOTOX ladder** — Nitrates first, then Botulinum toxin, then Operative sphincterotomy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.